Insider Selling: CeriBell, Inc. (NASDAQ:CBLL) Director Sells 11,188 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 11,188 shares of the business's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total transaction of $199,705.80. Following the completion of the sale, the director now owns 10,042 shares in the company, valued at $179,249.70. The trade was a 52.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CeriBell Trading Up 0.0%

NASDAQ:CBLL traded up $0.01 during trading hours on Friday, hitting $17.81. 72,212 shares of the stock traded hands, compared to its average volume of 281,151. The firm has a 50 day moving average price of $16.61 and a 200 day moving average price of $20.83. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. As a group, equities analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Trading of CeriBell

A number of hedge funds have recently made changes to their positions in CBLL. Rhumbline Advisers increased its stake in CeriBell by 26.5% in the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock valued at $300,000 after buying an additional 3,276 shares during the period. Quantbot Technologies LP acquired a new position in shares of CeriBell in the first quarter worth $175,000. Lord Abbett & CO. LLC raised its holdings in shares of CeriBell by 7.9% during the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock worth $6,138,000 after acquiring an additional 23,451 shares in the last quarter. Nuveen LLC acquired a new stake in CeriBell during the first quarter valued at $311,000. Finally, Swiss National Bank purchased a new position in CeriBell in the first quarter valued at about $467,000.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CBLL. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.